Efficacy and Safety of Peptide Vaccine in Prevention of SARS-CoV-2 Infection: Prospective Study among Healthcare Professionals

The pandemic caused by the new coronavirus infection remains the topical health issue and constitutes serious threat to the entire world. Nowadays, active immunization against new type of coronavirus infection continues in Russian Federation and in all other countries. Vaccination is the crucial component in comprehensive program for COVID-19 prevention and control. Mass immunization of population can prevent both admissions and hospitalization in conditions of high incidence of COVID-19 and thereby reduce the burden on the health system. Despite the remaining complications in combating the SARS-CoV-2 pandemic, preventive vaccination is by far the most effective method for protection against this infection Clinical studies on the efficacy of various preventive vaccinations in different regions of the world are extremely relevant especially under conditions of the emergency use authorization for vaccines against new coronavirus infection, the changing epidemiological situation, and the wide variability of different types of vaccines. All countries will need continuously updated data on vaccine efficacy to address new challenges such as weakening post-vaccine protection, new SARS-CoV-2 strains, and need for other preventive measures to mitigate the pandemic.

1. COVID-19 Coronavirus Pandemic. In: Worldometer. Available online: https://www.worldometers.info/coronavirus/#countries. Accessed on January, 19, 2022.

2. Information on cases of COVID-19 in Russia and the world. In: Rospotrebnadzor. (In Russ). Доступно по: https://www.rospotrebnadzor.ru/region/korono_virus/epid.php. Ссылка активна на 27.02.2022.

3. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage В beta-coronaviruses. Nat Microbiol. 2020;5(4):562–569. doi: https://doi.org/10.1038/s41564-020-0688-y

4. Moderbacher CR, Ramirez SI, Dan JM, et al. Antigenspecific adaptive immunity to SARSCoV2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19. doi: https://doi.org/10.1016/j.cell.2020.09.038

5. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021;600(7889):472–477. doi: https://doi.org/10.1038/s41586-021-03767-x

6. Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. doi: https://doi.org/10.3389/fpubh.2020.00152

7. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: https://doi.org/10.1136/bmj.m1985

8. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19 death in 17 million patients. Nature. 2020;584(7821):430–436. doi: https://doi.org/10.1038/s41586- 020-2521-4

9. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36:e3319. doi: https://doi.org/10.1002/dmrr.3319

10. Maddaloni E, Buzzetti R. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020;36:e3321. doi: https://doi.org/10.1002/dmrr.3321

11. Vaccine Market Dashboard. In: UNICEF. Available online: https://www.unicef.org/supply/covid-19-vaccine-marketdashboard. Accessed on January 19, 2022.

12. WHO. Coronavirus disease (COVID-19) advice for the public: Mythbusters. In: World Health Organization. 19 January 2022. (In Russ). Доступно по: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters. Ссылка активна на 27.02.2022.

13. 20th meeting of the European Technical Advisory Group of Experts on Immunization: virtual meeting 11–12 November 2020. Copenhagen: WHO Regional Office for Europe; 2021. (In Russ).Доступно по: https://apps.who.int/iris/bitstream/handle/10665/341394/WHO-EURO-2021-1808-41559-57119-rus.pdf. Ссылка активна на 27.02.2022.

14. WHO. Evaluation of COVID-19 vaccine effectiveness: Interim Guidance, 17 Marth 2021. Geneva: World Health Organization; 2021. (In Russ).Доступно по: https://apps.who.int/iris/bitstream/handle/10665/340301/WHO-2019-nCoV-vaccine-effectiveness-measurement-2021.1-rus.pdf. Ссылка активна на 27.02.2021.

15. Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of COVID-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244. doi: https://doi.org/10.1136/bmj.n2244

16. Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russian Journal of Infection and Immunity = Infektsiya i immunitet. 2021;11(2): 283–296. (In Russ). doi: https://doi.org/10.15789/2220-7619-ASB-1699

17. Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, et al. Immunogenicity and Protectivity of the Peptide Vaccine against SARS-CoV-2. Annals of the Russian Academy of Medical Sciences. 2021;76(1):5–19. (In Russ). doi: https://doi.org/10.15690/vramn1528

18. Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21(11):1539–48. doi: https://doi.org/10.1016/S1473-3099(21)00330-3

19. Barnabas RV, Wald A. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose. Ann Intern Med. 2021;174(4):552–553. doi: https://doi.org/10.7326/M20-8060

20. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829. doi: https://doi.org/10.1016/S0140-6736(21)00947-8

21. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275): 671–681. doi: https://doi.org/10.1016/S0140-6736(21)00234-8

22. COVID-19 vaccine surveillance report. Week 42. UK Health Security Agency; 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027511/Vaccine-surveillance-reportweek-42.pdf. Accessed on February 27, 2022.

23. Semenzato L, Botton J, Drouin J, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur. 2021;8:100158. doi: https://doi.org/10.1016/j.lanepe.2021.100158

24. Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):631. doi: https://doi.org/10.1038/s41467-020-19741-6

25. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782–793. doi: https://doi.org/10.1001/jama.2020.12839

26. Wall ЕC, Wu М, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331-2333. doi: https://doi.org/10.1016/S0140-6736(21)01290-3

27. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi: https://doi.org/10.1001/jamainternmed.2020.0994

28. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. doi: https://doi.org/10.1111/jth.14768

29. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440. doi: https://doi.org/10.1016/S2352-3026(20)30145-9

30. Kostinov M.P., Khromova E.A., Kostinova A.M. Could influenza vaccination be a non-specific prevention of SARS-CoV-2 and other respiratory infections? Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training. 2020;9(3):36–40. (In Russ). doi: https://doi.org/10.33029/2305-3496-2020-9-3-36-40

31. Voysey M, Clemens SAC, Madh SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111 doi: https://doi.org/10.1016/S0140-6736(20)32661-1

32. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383: 2603–2615. doi: https://doi.org/10.1056/NEJMoa2034577